---
annotation-target: blood.2022016867.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-29T02:59:50.882Z","updated":"2022-08-29T02:59:50.882Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":8328,"end":8348},{"type":"TextQuoteSelector","exact":"European LeukemiaNet","prefix":" Expert Panel, on Behalf of the ","suffix":"  Hartmut Döhner,1 Andrew H. Wei"}]}]}
>```
>%%
>*%%PREFIX%%Expert Panel, on Behalf of the%%HIGHLIGHT%% ==European LeukemiaNet== %%POSTFIX%%Hartmut Döhner,1 Andrew H. Wei*
>%%LINK%%[[#^5nuwjrzz7b4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5nuwjrzz7b4


>%%
>```annotation-json
>{"created":"2022-08-29T03:00:18.594Z","updated":"2022-08-29T03:00:18.594Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":11685,"end":12250},{"type":"TextQuoteSelector","exact":"There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update  of  the  disease  classification,  technological  progress  in  genomic  diagnostics  and assessment  of  measurable  residual  disease,  and  the  successful  development  of  new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted  this  update  which  includes  a  revised  ELN  genetic  risk  classification,  revised response criteria, and treatment recommendations.   ","prefix":"g physicians and investigators. ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%g physicians and investigators.%%HIGHLIGHT%% ==There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update  of  the  disease  classification,  technological  progress  in  genomic  diagnostics  and assessment  of  measurable  residual  disease,  and  the  successful  development  of  new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted  this  update  which  includes  a  revised  ELN  genetic  risk  classification,  revised response criteria, and treatment recommendations.== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^qb9qi7slj38|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qb9qi7slj38


>%%
>```annotation-json
>{"created":"2022-08-29T05:44:51.658Z","updated":"2022-08-29T05:44:51.658Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":12614,"end":13231},{"type":"TextQuoteSelector","exact":" These  advances  include  insights into  the  clinical  value  of  genomic  abnormalities  for  diagnosis  and  prognosis,  the  clinical significance  of  inherited  predisposition  to  AML,  technological  advancements  in  the quantitative assessment of measurable residual disease (MRD) and their utility for assessing therapeutic  response  and  disease  risk,  the  development  of  a  range  of  novel  therapeutic agents, and developments in allogeneic hematopoietic cell transplantation (HCT), resulting in new disease classification,2 diagnostic and prognostic algorithms, and updated therapeutic practices","prefix":" influence  clinical  practice. ","suffix":". The current report highlights "}]}]}
>```
>%%
>*%%PREFIX%%influence  clinical  practice.%%HIGHLIGHT%% ==These  advances  include  insights into  the  clinical  value  of  genomic  abnormalities  for  diagnosis  and  prognosis,  the  clinical significance  of  inherited  predisposition  to  AML,  technological  advancements  in  the quantitative assessment of measurable residual disease (MRD) and their utility for assessing therapeutic  response  and  disease  risk,  the  development  of  a  range  of  novel  therapeutic agents, and developments in allogeneic hematopoietic cell transplantation (HCT), resulting in new disease classification,2 diagnostic and prognostic algorithms, and updated therapeutic practices== %%POSTFIX%%. The current report highlights*
>%%LINK%%[[#^44ef8d6uwqa|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^44ef8d6uwqa


>%%
>```annotation-json
>{"created":"2022-08-29T05:46:27.166Z","updated":"2022-08-29T05:46:27.166Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":13765,"end":13783},{"type":"TextQuoteSelector","exact":"AML classification","prefix":"  respective recommendations.4  ","suffix":" Molecular landscape Somatic mut"}]}]}
>```
>%%
>*%%PREFIX%%respective recommendations.4%%HIGHLIGHT%% ==AML classification== %%POSTFIX%%Molecular landscape Somatic mut*
>%%LINK%%[[#^p821jr8zc97|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^p821jr8zc97


>%%
>```annotation-json
>{"created":"2022-08-29T05:48:56.932Z","text":"further investigate","updated":"2022-08-29T05:48:56.932Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":14521,"end":14968},{"type":"TextQuoteSelector","exact":"Although  some  mutations,  such  as  those  in DNMT3A, TET2, and ASXL1, are more common in clonal hematopoiesis and appear to be relatively early events in leukemogenesis, others tend to be acquired later in the course of leukemia development, including mutations in FLT3, NRAS, and RUNX1. The combinations of mutations that ultimately drive leukemogenesis are influenced by biological cooperativity and mutual exclusivity between mutated genes. ","prefix":"s  in  prevalence  with  age.7  ","suffix":"General classification The Inter"}]}]}
>```
>%%
>*%%PREFIX%%s  in  prevalence  with  age.7%%HIGHLIGHT%% ==Although  some  mutations,  such  as  those  in DNMT3A, TET2, and ASXL1, are more common in clonal hematopoiesis and appear to be relatively early events in leukemogenesis, others tend to be acquired later in the course of leukemia development, including mutations in FLT3, NRAS, and RUNX1. The combinations of mutations that ultimately drive leukemogenesis are influenced by biological cooperativity and mutual exclusivity between mutated genes.== %%POSTFIX%%General classification The Inter*
>%%LINK%%[[#^q9o10e9na3k|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^q9o10e9na3k


>%%
>```annotation-json
>{"created":"2022-08-29T05:52:24.225Z","updated":"2022-08-29T05:52:24.225Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":15129,"end":15209},{"type":"TextQuoteSelector","exact":" changes  in  the  blast  thresholds  and  new  genetic entities  to  define  AM","prefix":"ification  of  AML9  introduced ","suffix":"L,  further  expanding  the  spe"}]}]}
>```
>%%
>*%%PREFIX%%ification  of  AML9  introduced%%HIGHLIGHT%% ==changes  in  the  blast  thresholds  and  new  genetic entities  to  define  AM== %%POSTFIX%%L,  further  expanding  the  spe*
>%%LINK%%[[#^io3vqdztyys|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^io3vqdztyys


>%%
>```annotation-json
>{"created":"2022-08-29T05:53:18.382Z","updated":"2022-08-29T05:53:18.382Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":15447,"end":15629},{"type":"TextQuoteSelector","exact":" defining  AML  disease classification,  with  additional  pre-disposing  features  (therapy-related,  prior  MDS  or MDS/myeloproliferative neoplasm [MPN], germline predisposition) ","prefix":"tions  are  given  priority  in ","suffix":"appended as qualifiers of the pr"}]}]}
>```
>%%
>*%%PREFIX%%tions  are  given  priority  in%%HIGHLIGHT%% ==defining  AML  disease classification,  with  additional  pre-disposing  features  (therapy-related,  prior  MDS  or MDS/myeloproliferative neoplasm [MPN], germline predisposition)== %%POSTFIX%%appended as qualifiers of the pr*
>%%LINK%%[[#^qzv4g0fmhi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qzv4g0fmhi


>%%
>```annotation-json
>{"created":"2022-08-29T05:54:06.849Z","text":"10%????","updated":"2022-08-29T05:54:06.849Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":16033,"end":16234},{"type":"TextQuoteSelector","exact":"define specific subtypes of AML - with the exception of AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 - are now considered to establish a diagnosis of AML if there are ≥10% blasts in the bone marrow or blood","prefix":"ic abnormalities (Table 1) that ","suffix":". The clinical behavior of myelo"}]}]}
>```
>%%
>*%%PREFIX%%ic abnormalities (Table 1) that%%HIGHLIGHT%% ==define specific subtypes of AML - with the exception of AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 - are now considered to establish a diagnosis of AML if there are ≥10% blasts in the bone marrow or blood== %%POSTFIX%%. The clinical behavior of myelo*
>%%LINK%%[[#^ib916unvnoa|show annotation]]
>%%COMMENT%%
>10%????
>%%TAGS%%
>
^ib916unvnoa


>%%
>```annotation-json
>{"created":"2022-08-29T05:55:33.068Z","text":"further investigate","updated":"2022-08-29T05:55:33.068Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":16402,"end":16680},{"type":"TextQuoteSelector","exact":"  This  10%  blast  threshold  aligns  with previously  AML-defining  abnormalities,  such  as  PML::RARA,  CBFB::MYH11,  and RUNX1::RUNX1T1.19  To  avoid  potential  overlap  with  chronic  myeloid  leukemia  in accelerated phase, AML with BCR::ABL1 still requires ≥20% blasts.","prefix":"enting  with  <20%  blasts.10-18","suffix":" Although  all  other  AML  subt"}]}]}
>```
>%%
>*%%PREFIX%%enting  with  <20%  blasts.10-18%%HIGHLIGHT%% ==This  10%  blast  threshold  aligns  with previously  AML-defining  abnormalities,  such  as  PML::RARA,  CBFB::MYH11,  and RUNX1::RUNX1T1.19  To  avoid  potential  overlap  with  chronic  myeloid  leukemia  in accelerated phase, AML with BCR::ABL1 still requires ≥20% blasts.== %%POSTFIX%%Although  all  other  AML  subt*
>%%LINK%%[[#^e67tghsz2vd|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^e67tghsz2vd


>%%
>```annotation-json
>{"created":"2022-08-29T06:03:27.856Z","updated":"2022-08-29T06:03:27.856Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":16760,"end":17207},{"type":"TextQuoteSelector","exact":" new  category  of myelodysplastic  syndrome  (MDS)/AML  has  been  introduced  in  association  with  defined genomic abnormalities to include cases with 10-19% blasts in the bone marrow or blood, to recognize the fact that these cases lie on the border between AML and MDS in terms of their biology and prognosis (Table 1).20-25 Patients diagnosed with MDS/AML should be eligible for either MDS or AML clinical trials and treatment approaches.  ","prefix":"20%  blasts  for  diagnosis,  a ","suffix":"Antecedent AML history An import"}]}]}
>```
>%%
>*%%PREFIX%%20%  blasts  for  diagnosis,  a%%HIGHLIGHT%% ==new  category  of myelodysplastic  syndrome  (MDS)/AML  has  been  introduced  in  association  with  defined genomic abnormalities to include cases with 10-19% blasts in the bone marrow or blood, to recognize the fact that these cases lie on the border between AML and MDS in terms of their biology and prognosis (Table 1).20-25 Patients diagnosed with MDS/AML should be eligible for either MDS or AML clinical trials and treatment approaches.== %%POSTFIX%%Antecedent AML history An import*
>%%LINK%%[[#^t6t8ujgove|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^t6t8ujgove


>%%
>```annotation-json
>{"created":"2022-08-29T06:07:11.032Z","text":"祖先","updated":"2022-08-29T06:07:11.032Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":17207,"end":17217},{"type":"TextQuoteSelector","exact":"Antecedent","prefix":"ials and treatment approaches.  ","suffix":" AML history An important change"}]}]}
>```
>%%
>*%%PREFIX%%ials and treatment approaches.%%HIGHLIGHT%% ==Antecedent== %%POSTFIX%%AML history An important change*
>%%LINK%%[[#^j6m7bo1jqrb|show annotation]]
>%%COMMENT%%
>祖先
>%%TAGS%%
>
^j6m7bo1jqrb


>%%
>```annotation-json
>{"created":"2022-08-29T06:08:23.832Z","updated":"2022-08-29T06:08:23.832Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":17278,"end":17405},{"type":"TextQuoteSelector","exact":" removal of the former categories AML with myelodysplasia-related  changes  (AML-MRC)  and  therapy-related  myeloid  neoplasms","prefix":"nge to the classification is the","suffix":". Recent  data  indicate  that  "}]}]}
>```
>%%
>*%%PREFIX%%nge to the classification is the%%HIGHLIGHT%% ==removal of the former categories AML with myelodysplasia-related  changes  (AML-MRC)  and  therapy-related  myeloid  neoplasms== %%POSTFIX%%. Recent  data  indicate  that*
>%%LINK%%[[#^fue1jb8dqcm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^fue1jb8dqcm


>%%
>```annotation-json
>{"created":"2022-08-29T06:09:29.115Z","updated":"2022-08-29T06:09:29.115Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":17407,"end":17760},{"type":"TextQuoteSelector","exact":"Recent  data  indicate  that  genetic  characteristics,  rather  than  clinical  history  (de  novo, secondary after an antecedent MDS or MDS/MPN, or therapy-related), have most relevance in classifying biologically distinct AML subgroups.6,26 Dysplastic morphology, currently used as a criterion for AML-MRC, lacks independent prognostic significance.2","prefix":"py-related  myeloid  neoplasms. ","suffix":"7-29 Thus, although a prior hist"}]}]}
>```
>%%
>*%%PREFIX%%py-related  myeloid  neoplasms.%%HIGHLIGHT%% ==Recent  data  indicate  that  genetic  characteristics,  rather  than  clinical  history  (de  novo, secondary after an antecedent MDS or MDS/MPN, or therapy-related), have most relevance in classifying biologically distinct AML subgroups.6,26 Dysplastic morphology, currently used as a criterion for AML-MRC, lacks independent prognostic significance.2== %%POSTFIX%%7-29 Thus, although a prior hist*
>%%LINK%%[[#^goqoty9q4ne|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^goqoty9q4ne


>%%
>```annotation-json
>{"created":"2022-08-29T06:16:03.658Z","text":"further investigate","updated":"2022-08-29T06:16:03.658Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":18037,"end":18271},{"type":"TextQuoteSelector","exact":"This  category  has  been  expanded  to  include  additional  variant  translocations  involving RARA, KMT2A, and MECOM, as well as other rare recurring translocations, which are now recognized  as  AML-defining  entities  (Table  1).","prefix":"recurrent genetic abnormalities ","suffix":"14,30,31  Recent  studies  show "}]}]}
>```
>%%
>*%%PREFIX%%recurrent genetic abnormalities%%HIGHLIGHT%% ==This  category  has  been  expanded  to  include  additional  variant  translocations  involving RARA, KMT2A, and MECOM, as well as other rare recurring translocations, which are now recognized  as  AML-defining  entities  (Table  1).== %%POSTFIX%%14,30,31  Recent  studies  show*
>%%LINK%%[[#^7daw2c02f9|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^7daw2c02f9


>%%
>```annotation-json
>{"created":"2022-08-29T06:16:38.506Z","text":" leucine zipper 亮氨酸拉链\nbiallelic 双等位基因\nmonoallelic 单等位基因","updated":"2022-08-29T06:16:38.506Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":18310,"end":18636},{"type":"TextQuoteSelector","exact":"in-frame mutations  affecting  the  basic  leucine  zipper  (bZIP)  region  of  CEBPA  confer  a  favorable outcome, irrespective of their occurrence as biallelic or monoallelic mutations.32-35 In-frame bZIP  variants  are  found  in  90%  and  35%  of  cases  with  biallelic  and  monoallelic  CEBPA mutations, respectively.","prefix":"1  Recent  studies  show  that  ","suffix":" Gene expression analyses suppor"}]}]}
>```
>%%
>*%%PREFIX%%1  Recent  studies  show  that%%HIGHLIGHT%% ==in-frame mutations  affecting  the  basic  leucine  zipper  (bZIP)  region  of  CEBPA  confer  a  favorable outcome, irrespective of their occurrence as biallelic or monoallelic mutations.32-35 In-frame bZIP  variants  are  found  in  90%  and  35%  of  cases  with  biallelic  and  monoallelic  CEBPA mutations, respectively.== %%POSTFIX%%Gene expression analyses suppor*
>%%LINK%%[[#^jkchatjlz8|show annotation]]
>%%COMMENT%%
> leucine zipper 亮氨酸拉链
>biallelic 双等位基因
>monoallelic 单等位基因
>%%TAGS%%
>
^jkchatjlz8


>%%
>```annotation-json
>{"created":"2022-08-29T06:21:47.925Z","updated":"2022-08-29T06:21:47.925Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":18934,"end":19067},{"type":"TextQuoteSelector","exact":"AML with mutated TP53, AML with myelodysplasia-related gene mutations, and AML with myelodysplasia-related cytogenetic abnormalities ","prefix":"biallelic CEBPA abnormalities.  ","suffix":"Accumulating evidence indicates "}]}]}
>```
>%%
>*%%PREFIX%%biallelic CEBPA abnormalities.%%HIGHLIGHT%% ==AML with mutated TP53, AML with myelodysplasia-related gene mutations, and AML with myelodysplasia-related cytogenetic abnormalities== %%POSTFIX%%Accumulating evidence indicates*
>%%LINK%%[[#^37ps4lh698q|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^37ps4lh698q


>%%
>```annotation-json
>{"created":"2022-08-29T06:22:51.005Z","updated":"2022-08-29T06:22:51.005Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":19067,"end":19210},{"type":"TextQuoteSelector","exact":"Accumulating evidence indicates that from both a clinical and molecular perspective, TP53-mutant AML and MDS represent a distinct disease entit","prefix":"lated cytogenetic abnormalities ","suffix":"y. The vast majority of TP53-mut"}]}]}
>```
>%%
>*%%PREFIX%%lated cytogenetic abnormalities%%HIGHLIGHT%% ==Accumulating evidence indicates that from both a clinical and molecular perspective, TP53-mutant AML and MDS represent a distinct disease entit== %%POSTFIX%%y. The vast majority of TP53-mut*
>%%LINK%%[[#^0zb2bwsyvtib|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0zb2bwsyvtib


>%%
>```annotation-json
>{"created":"2022-08-29T06:23:02.490Z","updated":"2022-08-29T06:23:02.490Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":19295,"end":19450},{"type":"TextQuoteSelector","exact":" TP53 mutations occur in the absence of other AML-associated gene mutations. Clinically, these myeloid neoplasms are associated with a very poor prognosis.","prefix":"x karyotypes, and in about half,","suffix":"6,36-41 The presence of a pathog"}]}]}
>```
>%%
>*%%PREFIX%%x karyotypes, and in about half,%%HIGHLIGHT%% ==TP53 mutations occur in the absence of other AML-associated gene mutations. Clinically, these myeloid neoplasms are associated with a very poor prognosis.== %%POSTFIX%%6,36-41 The presence of a pathog*
>%%LINK%%[[#^1g11vfos3s6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1g11vfos3s6


>%%
>```annotation-json
>{"created":"2022-08-29T06:26:03.520Z","text":"further investigate","updated":"2022-08-29T06:26:03.520Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":19835,"end":20194},{"type":"TextQuoteSelector","exact":"Cases lacking TP53 mutation, but with mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 are categorized as AML with myelodysplasia-related gene  mutations,  irrespective  of  any  prior  history  of  MDS.  These  mutations  are  highly associated  with  AML  following  prior  MDS  or  MDS/MPN  and  confer  an adverse prognosis ","prefix":" entity AML with mutated TP53.  ","suffix":"even if they occur in de novo AM"}]}]}
>```
>%%
>*%%PREFIX%%entity AML with mutated TP53.%%HIGHLIGHT%% ==Cases lacking TP53 mutation, but with mutations in ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 are categorized as AML with myelodysplasia-related gene  mutations,  irrespective  of  any  prior  history  of  MDS.  These  mutations  are  highly associated  with  AML  following  prior  MDS  or  MDS/MPN  and  confer  an adverse prognosis== %%POSTFIX%%even if they occur in de novo AM*
>%%LINK%%[[#^ehtgi4x5ruu|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^ehtgi4x5ruu


>%%
>```annotation-json
>{"created":"2022-08-29T06:27:16.644Z","text":"包含了","updated":"2022-08-29T06:27:16.644Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":20286,"end":20297},{"type":"TextQuoteSelector","exact":"encompasses","prefix":"ysplasia-related gene mutations ","suffix":" the prior provisional category "}]}]}
>```
>%%
>*%%PREFIX%%ysplasia-related gene mutations%%HIGHLIGHT%% ==encompasses== %%POSTFIX%%the prior provisional category*
>%%LINK%%[[#^n10d1m4vg8|show annotation]]
>%%COMMENT%%
>包含了
>%%TAGS%%
>
^n10d1m4vg8


>%%
>```annotation-json
>{"created":"2022-08-29T06:29:20.420Z","updated":"2022-08-29T06:29:20.420Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":20882,"end":21055},{"type":"TextQuoteSelector","exact":"The  remaining  AML  cases  are  categorized  as  ‘AML,  not  otherwise  specified’  (AML-NOS) (irrespective  of  the  presence  or  absence  of  multilineage  dysplasia).  ","prefix":"ted cytogenetic abnormalities”. ","suffix":"The  four  categories described "}]}]}
>```
>%%
>*%%PREFIX%%ted cytogenetic abnormalities”.%%HIGHLIGHT%% ==The  remaining  AML  cases  are  categorized  as  ‘AML,  not  otherwise  specified’  (AML-NOS) (irrespective  of  the  presence  or  absence  of  multilineage  dysplasia).== %%POSTFIX%%The  four  categories described*
>%%LINK%%[[#^b3owsjwtaaj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^b3owsjwtaaj


>%%
>```annotation-json
>{"created":"2022-08-29T06:30:19.773Z","updated":"2022-08-29T06:30:19.773Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":21219,"end":21468},{"type":"TextQuoteSelector","exact":"Cases that have both a specific AML-defining  recurrent  genetic  abnormality  and  TP53  mutation  and/or  myelodysplasia-related  gene  mutations  or  cytogenetics  should  be  classified  according  to  the  defined recurrent genetic abnormality.","prefix":"20% blasts (Table 1; Figure 1). ","suffix":" Although complex karyotypes and"}]}]}
>```
>%%
>*%%PREFIX%%20% blasts (Table 1; Figure 1).%%HIGHLIGHT%% ==Cases that have both a specific AML-defining  recurrent  genetic  abnormality  and  TP53  mutation  and/or  myelodysplasia-related  gene  mutations  or  cytogenetics  should  be  classified  according  to  the  defined recurrent genetic abnormality.== %%POSTFIX%%Although complex karyotypes and*
>%%LINK%%[[#^brbw55a9er|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^brbw55a9er


>%%
>```annotation-json
>{"created":"2022-08-29T06:38:43.913Z","updated":"2022-08-29T06:38:43.913Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":22056,"end":22388},{"type":"TextQuoteSelector","exact":"ut the term “therapy-related” is now used as a diagnostic qualifier to the disease entities that are primarily defined by their genetic profile. These  neoplasms  have  been  thought  to  be  the  direct  consequence  of  mutational  events induced  by  cytotoxic  therapy  and/or  selection  of  chemotherapy-resistant  clones.48-5","prefix":"r considered a disease entity, b","suffix":"0  In  general, these AMLs are  "}]}]}
>```
>%%
>*%%PREFIX%%r considered a disease entity, b%%HIGHLIGHT%% ==ut the term “therapy-related” is now used as a diagnostic qualifier to the disease entities that are primarily defined by their genetic profile. These  neoplasms  have  been  thought  to  be  the  direct  consequence  of  mutational  events induced  by  cytotoxic  therapy  and/or  selection  of  chemotherapy-resistant  clones.48-5== %%POSTFIX%%0  In  general, these AMLs are*
>%%LINK%%[[#^k36lt9yxnhh|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^k36lt9yxnhh


>%%
>```annotation-json
>{"created":"2022-08-29T06:40:10.331Z","updated":"2022-08-29T06:40:10.331Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":22505,"end":22788},{"type":"TextQuoteSelector","exact":"2  The  more  common  subtype,  seen  in  ~75%  of  cases,  typically presents 5 to 7 years after first exposure to alkylating agents or radiation, is often preceded by MDS, and is frequently accompanied by chromosomes 5 and/or 7 abnormalities, complex karyotype, and TP53 mutations.","prefix":"show an abnormal  karyotype.51,5","suffix":"48,49,52,53 Some individuals dev"}]}]}
>```
>%%
>*%%PREFIX%%show an abnormal  karyotype.51,5%%HIGHLIGHT%% ==2  The  more  common  subtype,  seen  in  ~75%  of  cases,  typically presents 5 to 7 years after first exposure to alkylating agents or radiation, is often preceded by MDS, and is frequently accompanied by chromosomes 5 and/or 7 abnormalities, complex karyotype, and TP53 mutations.== %%POSTFIX%%48,49,52,53 Some individuals dev*
>%%LINK%%[[#^scxm56w1km|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^scxm56w1km


>%%
>```annotation-json
>{"created":"2022-08-29T06:41:01.089Z","updated":"2022-08-29T06:41:01.089Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":22797,"end":23049},{"type":"TextQuoteSelector","exact":"53 Some individuals develop t-AML after treatment with topoisomerase II inhibitors, with breakage at topo II sites leading to abnormal recombination and  balanced  translocations  involving  KMT2A  at  11q23,  RUNX1  at  21q22,  or  RARA  at  17q21.2. ","prefix":"pe, and TP53 mutations.48,49,52,","suffix":" In  these  cases,  the  latency"}]}]}
>```
>%%
>*%%PREFIX%%pe, and TP53 mutations.48,49,52,%%HIGHLIGHT%% ==53 Some individuals develop t-AML after treatment with topoisomerase II inhibitors, with breakage at topo II sites leading to abnormal recombination and  balanced  translocations  involving  KMT2A  at  11q23,  RUNX1  at  21q22,  or  RARA  at  17q21.2.== %%POSTFIX%%In  these  cases,  the  latency*
>%%LINK%%[[#^rh8wbarrf3c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rh8wbarrf3c


>%%
>```annotation-json
>{"created":"2022-08-29T06:45:04.083Z","updated":"2022-08-29T06:45:04.083Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":23296,"end":23351},{"type":"TextQuoteSelector","exact":"Clonal hematopoiesis of indeterminate potential may be ","prefix":"is resistant to chemotherapy.52 ","suffix":"the Downloaded from http://ashpu"}]}]}
>```
>%%
>*%%PREFIX%%is resistant to chemotherapy.52%%HIGHLIGHT%% ==Clonal hematopoiesis of indeterminate potential may be== %%POSTFIX%%the Downloaded from http://ashpu*
>%%LINK%%[[#^zr83yqcqd4g|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zr83yqcqd4g


>%%
>```annotation-json
>{"created":"2022-08-29T06:45:56.347Z","updated":"2022-08-29T06:45:56.347Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":23580,"end":23770},{"type":"TextQuoteSelector","exact":"5 Cases were identified in which the exact TP53 mutation found  at  diagnosis  was  already  present  at  low  frequency  in  blood  or  bone  marrow  many years  before  t-AML  development.","prefix":"t step in a multi-hit model.54,5","suffix":"51  These  data  suggest  a  mod"}]}]}
>```
>%%
>*%%PREFIX%%t step in a multi-hit model.54,5%%HIGHLIGHT%% ==5 Cases were identified in which the exact TP53 mutation found  at  diagnosis  was  already  present  at  low  frequency  in  blood  or  bone  marrow  many years  before  t-AML  development.== %%POSTFIX%%51  These  data  suggest  a  mod*
>%%LINK%%[[#^hw8zkimr1v|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^hw8zkimr1v


>%%
>```annotation-json
>{"created":"2022-08-29T06:47:52.399Z","updated":"2022-08-29T06:47:52.399Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":23795,"end":24145},{"type":"TextQuoteSelector","exact":" a  model  in  which  hematopoietic stem  cells  carrying  mutations  in  TP53  or  PPM1D  undergo  positive  selection  by  cytotoxic therapy, ultimately leading to t-AML.56,57 Mutations in the RAS/MAPK pathway, alterations in RUNX1 or TP53, and KMT2A rearrangements are also frequent somatic drivers in pediatric AML  related  to  previous  therapy","prefix":"opment.51  These  data  suggest ","suffix":",  but  unlike  in  adults,  mos"}]}]}
>```
>%%
>*%%PREFIX%%opment.51  These  data  suggest%%HIGHLIGHT%% ==a  model  in  which  hematopoietic stem  cells  carrying  mutations  in  TP53  or  PPM1D  undergo  positive  selection  by  cytotoxic therapy, ultimately leading to t-AML.56,57 Mutations in the RAS/MAPK pathway, alterations in RUNX1 or TP53, and KMT2A rearrangements are also frequent somatic drivers in pediatric AML  related  to  previous  therapy== %%POSTFIX%%,  but  unlike  in  adults,  mos*
>%%LINK%%[[#^dbd7a18lm5p|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dbd7a18lm5p


>%%
>```annotation-json
>{"created":"2022-08-29T06:52:48.160Z","updated":"2022-08-29T06:52:48.160Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":24311,"end":24523},{"type":"TextQuoteSelector","exact":"Deleterious mutations typical of familial cancer predisposition syndromes in the homologous recombination DNA repair pathway, particularly BRCA1, BRCA2, PALB2, TP53, or CHEK2, are  observed  in  ~20%  of  cases.5","prefix":"ot pre-existing minor clones.50 ","suffix":"8,59  The  identification  of  s"}]}]}
>```
>%%
>*%%PREFIX%%ot pre-existing minor clones.50%%HIGHLIGHT%% ==Deleterious mutations typical of familial cancer predisposition syndromes in the homologous recombination DNA repair pathway, particularly BRCA1, BRCA2, PALB2, TP53, or CHEK2, are  observed  in  ~20%  of  cases.5== %%POSTFIX%%8,59  The  identification  of  s*
>%%LINK%%[[#^8ymktes13pd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^8ymktes13pd


>%%
>```annotation-json
>{"created":"2022-08-29T06:54:07.929Z","text":"生殖系倾向","updated":"2022-08-29T06:54:07.929Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":24798,"end":24821},{"type":"TextQuoteSelector","exact":"Germline predisposition","prefix":"cade testing within families.60 ","suffix":" Increasingly, individuals are b"}]}]}
>```
>%%
>*%%PREFIX%%cade testing within families.60%%HIGHLIGHT%% ==Germline predisposition== %%POSTFIX%%Increasingly, individuals are b*
>%%LINK%%[[#^cgxpdvmgaf6|show annotation]]
>%%COMMENT%%
>生殖系倾向
>%%TAGS%%
>
^cgxpdvmgaf6


>%%
>```annotation-json
>{"created":"2022-08-29T06:58:33.039Z","updated":"2022-08-29T06:58:33.039Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":26068,"end":26335},{"type":"TextQuoteSelector","exact":"Clinicians  should  familiarize themselves  with  academic  and  commercial  testing  options,  including  the  culture  and sequencing of skin fibroblasts, thereby excluding somatic mutations in hematopoietic cells, and the panel of genes to be analyzed (Table 2).63","prefix":"ing  are  given  in  Table  3.  ","suffix":"  Germline variants are categori"}]}]}
>```
>%%
>*%%PREFIX%%ing  are  given  in  Table  3.%%HIGHLIGHT%% ==Clinicians  should  familiarize themselves  with  academic  and  commercial  testing  options,  including  the  culture  and sequencing of skin fibroblasts, thereby excluding somatic mutations in hematopoietic cells, and the panel of genes to be analyzed (Table 2).63== %%POSTFIX%%Germline variants are categori*
>%%LINK%%[[#^qilh557e1fi|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qilh557e1fi


>%%
>```annotation-json
>{"created":"2022-08-29T07:14:43.874Z","updated":"2022-08-29T07:14:43.874Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":26886,"end":27191},{"type":"TextQuoteSelector","exact":"Certain germline disorders are associated with specific characteristics that are important for clinicians to recognize (Table 2), those associated with quantitative and qualitative platelet defects: ANKRD26, ETV6, and RUNX1, and those associated with other organ dysfunction: GATA2  with  immunodeficiency","prefix":"kely pathogenic or pathogenic.  ","suffix":";  Shwachman  Diamond  Syndrome "}]}]}
>```
>%%
>*%%PREFIX%%kely pathogenic or pathogenic.%%HIGHLIGHT%% ==Certain germline disorders are associated with specific characteristics that are important for clinicians to recognize (Table 2), those associated with quantitative and qualitative platelet defects: ANKRD26, ETV6, and RUNX1, and those associated with other organ dysfunction: GATA2  with  immunodeficiency== %%POSTFIX%%;  Shwachman  Diamond  Syndrome*
>%%LINK%%[[#^nndl53zy4t8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nndl53zy4t8


>%%
>```annotation-json
>{"created":"2022-08-29T07:17:01.775Z","updated":"2022-08-29T07:17:01.775Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":27979,"end":28125},{"type":"TextQuoteSelector","exact":"Germline  predisposition alleles that confer risk to lymphoid malignancies are emerging and often overlap with the myeloid malignancy risk genes. ","prefix":"nd  families  are  identified.  ","suffix":"Because  the  treatment  plan  f"}]}]}
>```
>%%
>*%%PREFIX%%nd  families  are  identified.%%HIGHLIGHT%% ==Germline  predisposition alleles that confer risk to lymphoid malignancies are emerging and often overlap with the myeloid malignancy risk genes.== %%POSTFIX%%Because  the  treatment  plan  f*
>%%LINK%%[[#^e46bwii3rci|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^e46bwii3rci


>%%
>```annotation-json
>{"created":"2022-08-29T07:17:51.033Z","updated":"2022-08-29T07:17:51.033Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":28125,"end":28840},{"type":"TextQuoteSelector","exact":"Because  the  treatment  plan  for  many  patients  with  AML  includes  allogeneic  HCT  and relatives are the preferred donors, testing for germline risk alleles should be performed as early as possible during clinical management. Use of hematopoietic donor stem cells from carriers of deleterious RUNX1 and CEBPA variants is prohibitive, but we lack data for most predisposition genes and whether any  variants are permissive to transplantation.66 Future studies that lead to a comprehensive list of all predisposition genes will advance our ability to provide  the  best  treatments  for  patients  and  their  families  and  will  facilitate  strategies  to maintain health for them throughout their lifetimes.","prefix":" myeloid malignancy risk genes. ","suffix":"  Diagnostic procedures All test"}]}]}
>```
>%%
>*%%PREFIX%%myeloid malignancy risk genes.%%HIGHLIGHT%% ==Because  the  treatment  plan  for  many  patients  with  AML  includes  allogeneic  HCT  and relatives are the preferred donors, testing for germline risk alleles should be performed as early as possible during clinical management. Use of hematopoietic donor stem cells from carriers of deleterious RUNX1 and CEBPA variants is prohibitive, but we lack data for most predisposition genes and whether any  variants are permissive to transplantation.66 Future studies that lead to a comprehensive list of all predisposition genes will advance our ability to provide  the  best  treatments  for  patients  and  their  families  and  will  facilitate  strategies  to maintain health for them throughout their lifetimes.== %%POSTFIX%%Diagnostic procedures All test*
>%%LINK%%[[#^iyq47tv2z3b|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^iyq47tv2z3b


>%%
>```annotation-json
>{"created":"2022-08-29T07:19:09.117Z","updated":"2022-08-29T07:19:09.117Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":29040,"end":29199},{"type":"TextQuoteSelector","exact":"Immunophenotyping by multiparameter flow cytometry (MFC) is required to diagnose AML accurately  by  identifying  cell  surface  and  intracellular  markers  (","prefix":"d in Table 4. Immunophenotyping ","suffix":"Table  5).  Due  to  the heterog"}]}]}
>```
>%%
>*%%PREFIX%%d in Table 4. Immunophenotyping%%HIGHLIGHT%% ==Immunophenotyping by multiparameter flow cytometry (MFC) is required to diagnose AML accurately  by  identifying  cell  surface  and  intracellular  markers  (== %%POSTFIX%%Table  5).  Due  to  the heterog*
>%%LINK%%[[#^0d88ifkjr85d|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0d88ifkjr85d


>%%
>```annotation-json
>{"created":"2022-08-29T07:19:41.999Z","updated":"2022-08-29T07:19:41.999Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":29282,"end":29567},{"type":"TextQuoteSelector","exact":" It is also important to identify leukemia-associated immunophenotypes (LAIP) for subsequent MRD monitoring by MFC. In cases  where  an  aspirate  is  unobtainable  and  circulating  blasts  are  absent,  myeloid phenotype may be confirmed on a core biopsy using immunohistochemistry. ","prefix":"arker is expressed in all cases.","suffix":"Cytogenetic and molecular studie"}]}]}
>```
>%%
>*%%PREFIX%%arker is expressed in all cases.%%HIGHLIGHT%% ==It is also important to identify leukemia-associated immunophenotypes (LAIP) for subsequent MRD monitoring by MFC. In cases  where  an  aspirate  is  unobtainable  and  circulating  blasts  are  absent,  myeloid phenotype may be confirmed on a core biopsy using immunohistochemistry.== %%POSTFIX%%Cytogenetic and molecular studie*
>%%LINK%%[[#^rejrisbxxqk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rejrisbxxqk


>%%
>```annotation-json
>{"created":"2022-08-29T07:20:42.606Z","updated":"2022-08-29T07:20:42.606Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":29601,"end":30006},{"type":"TextQuoteSelector","exact":"Conventional  cytogenetic  analysis  is  mandatory  in  the  evaluation  of  AML.  If  conventional cytogenetics  fails,  fluorescence  in-situ  hybridization  is  an  alternative  to  detect  specific abnormalities like  RUNX1::RUNX1T1, CBFB::MYH11, KMT2A (MLL), and  MECOM (EVI1) gene fusions, or myelodysplasia-related chromosome abnormalities, eg, loss of chromosome 5q, 7q, or 17p material (Table 1).","prefix":"togenetic and molecular studies ","suffix":" Molecular genetic testing shoul"}]}]}
>```
>%%
>*%%PREFIX%%togenetic and molecular studies%%HIGHLIGHT%% ==Conventional  cytogenetic  analysis  is  mandatory  in  the  evaluation  of  AML.  If  conventional cytogenetics  fails,  fluorescence  in-situ  hybridization  is  an  alternative  to  detect  specific abnormalities like  RUNX1::RUNX1T1, CBFB::MYH11, KMT2A (MLL), and  MECOM (EVI1) gene fusions, or myelodysplasia-related chromosome abnormalities, eg, loss of chromosome 5q, 7q, or 17p material (Table 1).== %%POSTFIX%%Molecular genetic testing shoul*
>%%LINK%%[[#^2tptukkkej9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2tptukkkej9


>%%
>```annotation-json
>{"created":"2022-08-29T07:25:26.771Z","updated":"2022-08-29T07:25:26.771Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":30007,"end":30172},{"type":"TextQuoteSelector","exact":"Molecular genetic testing should screen for all the genetic abnormalities that define disease and risk categories or that are needed for targeted treatment modalitie","prefix":" 7q, or 17p material (Table 1). ","suffix":"s (Table 4). These tests  can  b"}]}]}
>```
>%%
>*%%PREFIX%%7q, or 17p material (Table 1).%%HIGHLIGHT%% ==Molecular genetic testing should screen for all the genetic abnormalities that define disease and risk categories or that are needed for targeted treatment modalitie== %%POSTFIX%%s (Table 4). These tests  can  b*
>%%LINK%%[[#^v5ge2l64n9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^v5ge2l64n9


>%%
>```annotation-json
>{"created":"2022-08-29T07:26:00.099Z","updated":"2022-08-29T07:26:00.099Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":30350,"end":30816},{"type":"TextQuoteSelector","exact":"When  AML  with  germline predisposition  is  suspected,  a  dedicated  gene  panel  including  known  predisposing  alleles should  be  used.  However,  caution  should  be  used  in  interpreting  data  from  tumor-based panels, since hematopoietic tissues undergo somatic reversion frequently leading to false-negative results, and panel-based testing is often not able to detect germline copy number variants, which are relatively common predisposition alleles. ","prefix":"utations  and  rearrangements.  ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%utations  and  rearrangements.%%HIGHLIGHT%% ==When  AML  with  germline predisposition  is  suspected,  a  dedicated  gene  panel  including  known  predisposing  alleles should  be  used.  However,  caution  should  be  used  in  interpreting  data  from  tumor-based panels, since hematopoietic tissues undergo somatic reversion frequently leading to false-negative results, and panel-based testing is often not able to detect germline copy number variants, which are relatively common predisposition alleles.== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^guvtujqxk6p|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^guvtujqxk6p


>%%
>```annotation-json
>{"created":"2022-08-29T07:27:14.136Z","updated":"2022-08-29T07:27:14.136Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":31005,"end":31254},{"type":"TextQuoteSelector","exact":"For patients with mutant NPM1 and core-binding factor (CBF)-AML, it is recommended to perform baseline molecular assessment by quantitative polymerase chain reaction (qPCR) or droplet digital PCR (dPCR) to facilitate MRD monitoring after treatment. ","prefix":"ecommendations  Page 8 of 54   8","suffix":"Biobanking At least in clinical "}]}]}
>```
>%%
>*%%PREFIX%%ecommendations  Page 8 of 54   8%%HIGHLIGHT%% ==For patients with mutant NPM1 and core-binding factor (CBF)-AML, it is recommended to perform baseline molecular assessment by quantitative polymerase chain reaction (qPCR) or droplet digital PCR (dPCR) to facilitate MRD monitoring after treatment.== %%POSTFIX%%Biobanking At least in clinical*
>%%LINK%%[[#^nws0tom9t2|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^nws0tom9t2


>%%
>```annotation-json
>{"created":"2022-08-29T07:32:13.638Z","updated":"2022-08-29T07:32:13.638Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":31337,"end":31540},{"type":"TextQuoteSelector","exact":"bone marrow and blood samples should be obtained at time of diagnosis, at remission and at relapse and stored under appropriate conditions (DNA and RNA stored at -80°C, and viable cells stored at -196°C)","prefix":"ably also outside this context, ","suffix":". Broad informed consent should "}]}]}
>```
>%%
>*%%PREFIX%%ably also outside this context,%%HIGHLIGHT%% ==bone marrow and blood samples should be obtained at time of diagnosis, at remission and at relapse and stored under appropriate conditions (DNA and RNA stored at -80°C, and viable cells stored at -196°C)== %%POSTFIX%%. Broad informed consent should*
>%%LINK%%[[#^ou4zo8oeb78|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ou4zo8oeb78


>%%
>```annotation-json
>{"created":"2022-08-29T07:33:37.420Z","updated":"2022-08-29T07:33:37.420Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":31918,"end":32098},{"type":"TextQuoteSelector","exact":"n addition to baseline genetic characterization, the importance of response to initial therapy and  assessment  of  early  MRD  in  individual  risk  assignment  are  highlighted.6","prefix":"djust the risk classification. I","suffix":"7  In  clinical  practice, a pat"}]}]}
>```
>%%
>*%%PREFIX%%djust the risk classification. I%%HIGHLIGHT%% ==n addition to baseline genetic characterization, the importance of response to initial therapy and  assessment  of  early  MRD  in  individual  risk  assignment  are  highlighted.6== %%POSTFIX%%7  In  clinical  practice, a pat*
>%%LINK%%[[#^dwgitufv9pd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dwgitufv9pd


>%%
>```annotation-json
>{"created":"2022-08-29T07:34:54.135Z","updated":"2022-08-29T07:34:54.135Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":32463,"end":32703},{"type":"TextQuoteSelector","exact":" The FLT3-ITD allelic ratio is no longer considered in the risk classification; consequently, all AML with FLT3-ITD are now categorized in the intermediate-risk group, irrespective of the allelic ratio or concurrent presence of NPM1 mutatio","prefix":"tion are outlined in Table 6. 1)","suffix":"n. The reason for this change re"}]}]}
>```
>%%
>*%%PREFIX%%tion are outlined in Table 6. 1)%%HIGHLIGHT%% ==The FLT3-ITD allelic ratio is no longer considered in the risk classification; consequently, all AML with FLT3-ITD are now categorized in the intermediate-risk group, irrespective of the allelic ratio or concurrent presence of NPM1 mutatio== %%POSTFIX%%n. The reason for this change re*
>%%LINK%%[[#^s9hrx4ujcrs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^s9hrx4ujcrs


>%%
>```annotation-json
>{"created":"2022-08-29T07:37:03.342Z","updated":"2022-08-29T07:37:03.342Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":32979,"end":33595},{"type":"TextQuoteSelector","exact":"AML with myelodysplasia-related gene mutations  is  now  categorized  in  the  adverse-risk  group.  These  mutations,  typically associated with AML following an antecedent hematologic disease, are also prevalent in de novo  AML  and  indicate  adverse  risk  even  in  the  absence  of  myelodysplasia-related cytogenetic abnormalities.6,26,42,44,45 Beyond the previously considered ASXL1 and/or RUNX1 genes,  this  category  of  myelodysplasia-related  gene  mutations  now  includes  pathologic variants  in  at  least  one  of  the  ASXL1,  BCOR,  EZH2,  RUNX1,  SF3B1,  SRSF2,  STAG2,  U2AF1,  or  ZRSR2  genes","prefix":" MRD in treatment decisions. 2) ","suffix":".  3)  The  presence  of  advers"}]}]}
>```
>%%
>*%%PREFIX%%MRD in treatment decisions. 2)%%HIGHLIGHT%% ==AML with myelodysplasia-related gene mutations  is  now  categorized  in  the  adverse-risk  group.  These  mutations,  typically associated with AML following an antecedent hematologic disease, are also prevalent in de novo  AML  and  indicate  adverse  risk  even  in  the  absence  of  myelodysplasia-related cytogenetic abnormalities.6,26,42,44,45 Beyond the previously considered ASXL1 and/or RUNX1 genes,  this  category  of  myelodysplasia-related  gene  mutations  now  includes  pathologic variants  in  at  least  one  of  the  ASXL1,  BCOR,  EZH2,  RUNX1,  SF3B1,  SRSF2,  STAG2,  U2AF1,  or  ZRSR2  genes== %%POSTFIX%%.  3)  The  presence  of  advers*
>%%LINK%%[[#^jg22pwgl4dp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^jg22pwgl4dp


>%%
>```annotation-json
>{"created":"2022-08-29T07:39:10.318Z","updated":"2022-08-29T07:39:10.318Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":33748,"end":33838},{"type":"TextQuoteSelector","exact":" NPM1-mutated AML with adverse cytogenetic abnormalities is associated with a poor outcome","prefix":"meta-analysis  has  shown  that ","suffix":".72 Whether other genetic abnorm"}]}]}
>```
>%%
>*%%PREFIX%%meta-analysis  has  shown  that%%HIGHLIGHT%% ==NPM1-mutated AML with adverse cytogenetic abnormalities is associated with a poor outcome== %%POSTFIX%%.72 Whether other genetic abnorm*
>%%LINK%%[[#^1gtsh5frwq3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1gtsh5frwq3


>%%
>```annotation-json
>{"created":"2022-08-29T07:39:37.299Z","updated":"2022-08-29T07:39:37.299Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":34051,"end":34298},{"type":"TextQuoteSelector","exact":" in-frame mutations affecting the basic leucine zipper region of  CEBPA  confer  the  favorable  outcome,  irrespective  of  their  occurrence  as  biallelic  or monoallelic mutations and therefore are now categorized in the favorable-risk group.3","prefix":", recent studies have shown that","suffix":"2,34,35 5) Additional disease-de"}]}]}
>```
>%%
>*%%PREFIX%%, recent studies have shown that%%HIGHLIGHT%% ==in-frame mutations affecting the basic leucine zipper region of  CEBPA  confer  the  favorable  outcome,  irrespective  of  their  occurrence  as  biallelic  or monoallelic mutations and therefore are now categorized in the favorable-risk group.3== %%POSTFIX%%2,34,35 5) Additional disease-de*
>%%LINK%%[[#^zretceswiyp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zretceswiyp


>%%
>```annotation-json
>{"created":"2022-08-29T07:40:27.990Z","updated":"2022-08-29T07:40:27.990Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":34309,"end":34542},{"type":"TextQuoteSelector","exact":"Additional disease-defining recurring cytogenetic abnormalities are included in the adverse-risk  group,  including  t(3q26.2;v)  involving  the  MECOM  gene,31,73  or  t(8;16)(p11;p13) associated  with  KAT6A::CREBBP  gene  fusion.1","prefix":"avorable-risk group.32,34,35 5) ","suffix":"4  6)  Finally,  hyperdiploid  k"}]}]}
>```
>%%
>*%%PREFIX%%avorable-risk group.32,34,35 5)%%HIGHLIGHT%% ==Additional disease-defining recurring cytogenetic abnormalities are included in the adverse-risk  group,  including  t(3q26.2;v)  involving  the  MECOM  gene,31,73  or  t(8;16)(p11;p13) associated  with  KAT6A::CREBBP  gene  fusion.1== %%POSTFIX%%4  6)  Finally,  hyperdiploid  k*
>%%LINK%%[[#^dbi18eir7mc|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dbi18eir7mc


>%%
>```annotation-json
>{"created":"2022-08-29T07:40:41.041Z","updated":"2022-08-29T07:40:41.041Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":34559,"end":34692},{"type":"TextQuoteSelector","exact":"hyperdiploid  karyotypes  with multiple trisomies (or polysomies) are no longer considered as complex karyotypes and as adverse-risk.","prefix":" gene  fusion.14  6)  Finally,  ","suffix":"74 Downloaded from http://ashpub"}]}]}
>```
>%%
>*%%PREFIX%%gene  fusion.14  6)  Finally,%%HIGHLIGHT%% ==hyperdiploid  karyotypes  with multiple trisomies (or polysomies) are no longer considered as complex karyotypes and as adverse-risk.== %%POSTFIX%%74 Downloaded from http://ashpub*
>%%LINK%%[[#^0422uu1f86n5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0422uu1f86n5


>%%
>```annotation-json
>{"created":"2022-08-29T07:41:18.284Z","updated":"2022-08-29T07:41:18.284Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":34961,"end":35211},{"type":"TextQuoteSelector","exact":"IDH1/IDH2 or  DNMT3A,  current  evidence  does  not  yet  warrant  their  assignment  to  a  distinct  ELN prognostic  group.  Also,  the  emerging  therapeutic  use  of  targeted  inhibitors  might  impact prognostic outcome in IDH1/IDH2-mutated AML","prefix":"ons in other genes, for example ","suffix":". Finally, it should be emphasiz"}]}]}
>```
>%%
>*%%PREFIX%%ons in other genes, for example%%HIGHLIGHT%% ==IDH1/IDH2 or  DNMT3A,  current  evidence  does  not  yet  warrant  their  assignment  to  a  distinct  ELN prognostic  group.  Also,  the  emerging  therapeutic  use  of  targeted  inhibitors  might  impact prognostic outcome in IDH1/IDH2-mutated AML== %%POSTFIX%%. Finally, it should be emphasiz*
>%%LINK%%[[#^47yxl8cskc6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^47yxl8cskc6


>%%
>```annotation-json
>{"created":"2022-08-29T07:46:42.018Z","updated":"2022-08-29T07:46:42.018Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":35456,"end":35484},{"type":"TextQuoteSelector","exact":"measurable residual disease ","prefix":"nsive therapies.  Monitoring of ","suffix":"MRD assessment in AML is used to"}]}]}
>```
>%%
>*%%PREFIX%%nsive therapies.  Monitoring of%%HIGHLIGHT%% ==measurable residual disease== %%POSTFIX%%MRD assessment in AML is used to*
>%%LINK%%[[#^k1blounk8pm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^k1blounk8pm


>%%
>```annotation-json
>{"created":"2022-08-29T07:54:06.263Z","updated":"2022-08-29T07:54:06.263Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":36109,"end":36300},{"type":"TextQuoteSelector","exact":"  MRD  includes  new  technical recommendations  for  standardized  MFC-MRD  and  Mol-MRD  analysis,  MRD  thresholds, definitions of MRD response and suggestions for clinical implications.67","prefix":"of  the  ELN  recommendation  on","suffix":" Multiparameter flow cytometry  "}]}]}
>```
>%%
>*%%PREFIX%%of  the  ELN  recommendation  on%%HIGHLIGHT%% ==MRD  includes  new  technical recommendations  for  standardized  MFC-MRD  and  Mol-MRD  analysis,  MRD  thresholds, definitions of MRD response and suggestions for clinical implications.67== %%POSTFIX%%Multiparameter flow cytometry*
>%%LINK%%[[#^zk9ah2vp2y|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zk9ah2vp2y


>%%
>```annotation-json
>{"created":"2022-08-29T07:56:06.231Z","updated":"2022-08-29T07:56:06.231Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":36772,"end":37215},{"type":"TextQuoteSelector","exact":"Evaluation of residual leukemic  stem  cells  (LSC)  by  MFC-MRD  is  still  investigational  but  is  recommended  for evaluation in clinical studies. The prognostic value of LSC-MRD has been associated with a higher sensitivity and lower false negativity.79,80 LSC can be immunophenotypically defined as CD34+/CD38low cells combined with an aberrant marker not present on normal HSCs, eg, CD45RA (PTPRC), CLL-1 (CLEC12A), or CD123 (IL3RA).81","prefix":"nes for rare event detection.78 ","suffix":" Molecular MRD The technique use"}]}]}
>```
>%%
>*%%PREFIX%%nes for rare event detection.78%%HIGHLIGHT%% ==Evaluation of residual leukemic  stem  cells  (LSC)  by  MFC-MRD  is  still  investigational  but  is  recommended  for evaluation in clinical studies. The prognostic value of LSC-MRD has been associated with a higher sensitivity and lower false negativity.79,80 LSC can be immunophenotypically defined as CD34+/CD38low cells combined with an aberrant marker not present on normal HSCs, eg, CD45RA (PTPRC), CLL-1 (CLEC12A), or CD123 (IL3RA).81== %%POSTFIX%%Molecular MRD The technique use*
>%%LINK%%[[#^wc2aexjr75i|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^wc2aexjr75i


>%%
>```annotation-json
>{"created":"2022-08-29T07:59:11.372Z","updated":"2022-08-29T07:59:11.372Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":37259,"end":37324},{"type":"TextQuoteSelector","exact":" qPCR and dPCR, should reach a limit of detection of at least 10-","prefix":"RD The technique used, including","suffix":"3. Either peripheral blood or bo"}]}]}
>```
>%%
>*%%PREFIX%%RD The technique used, including%%HIGHLIGHT%% ==qPCR and dPCR, should reach a limit of detection of at least 10-== %%POSTFIX%%3. Either peripheral blood or bo*
>%%LINK%%[[#^2tokuahji5p|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2tokuahji5p


>%%
>```annotation-json
>{"created":"2022-08-29T08:00:10.580Z","updated":"2022-08-29T08:00:10.580Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":37489,"end":37797},{"type":"TextQuoteSelector","exact":"Leukemia-related abnormalities  suitable  for  qPCR  monitoring  include  mutated  NPM1;  CBFB::MYH11, RUNX1::RUNX1T1, KMT2A::MLLT3, DEK::NUP214, and BCR::ABL1 gene fusions; and WT1 expression.67  Validation  is  most  robust  for  NPM1-mutated,  as  well  as  CBFB::MYH11  and RUNX1::RUNX1T1-positive AML.82","prefix":"e  compared  to  bone  marrow.  ","suffix":" If using NGS, error-corrected t"}]}]}
>```
>%%
>*%%PREFIX%%e  compared  to  bone  marrow.%%HIGHLIGHT%% ==Leukemia-related abnormalities  suitable  for  qPCR  monitoring  include  mutated  NPM1;  CBFB::MYH11, RUNX1::RUNX1T1, KMT2A::MLLT3, DEK::NUP214, and BCR::ABL1 gene fusions; and WT1 expression.67  Validation  is  most  robust  for  NPM1-mutated,  as  well  as  CBFB::MYH11  and RUNX1::RUNX1T1-positive AML.82== %%POSTFIX%%If using NGS, error-corrected t*
>%%LINK%%[[#^3id8hwi1lae|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^3id8hwi1lae


>%%
>```annotation-json
>{"created":"2022-08-29T08:01:30.309Z","updated":"2022-08-29T08:01:30.309Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":37949,"end":38232},{"type":"TextQuoteSelector","exact":"Mutations  consistent  with  pre-malignant clonal hematopoiesis (eg, DNMT3A, TET2, ASXL1) should not be considered as MRD.84  Further  study  is  required  to  identify  and  distinguish  mutations  truly  indicative  of residual AML from clonal hematopoiesis related abnormalities.8","prefix":" exclude  germline  mutations.  ","suffix":"5,86 It is important to note tha"}]}]}
>```
>%%
>*%%PREFIX%%exclude  germline  mutations.%%HIGHLIGHT%% ==Mutations  consistent  with  pre-malignant clonal hematopoiesis (eg, DNMT3A, TET2, ASXL1) should not be considered as MRD.84  Further  study  is  required  to  identify  and  distinguish  mutations  truly  indicative  of residual AML from clonal hematopoiesis related abnormalities.8== %%POSTFIX%%5,86 It is important to note tha*
>%%LINK%%[[#^zaluoa9wnqg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^zaluoa9wnqg


>%%
>```annotation-json
>{"created":"2022-08-29T08:05:12.741Z","updated":"2022-08-29T08:05:12.741Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":38659,"end":38733},{"type":"TextQuoteSelector","exact":" complete remission (CR) or CR with incomplete hematologic recovery (CRi) ","prefix":"nostic value of MRD detection in","suffix":"has been demonstrated both in pa"}]}]}
>```
>%%
>*%%PREFIX%%nostic value of MRD detection in%%HIGHLIGHT%% ==complete remission (CR) or CR with incomplete hematologic recovery (CRi)== %%POSTFIX%%has been demonstrated both in pa*
>%%LINK%%[[#^mbq14el5t5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mbq14el5t5


>%%
>```annotation-json
>{"created":"2022-08-29T08:06:45.842Z","updated":"2022-08-29T08:06:45.842Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":39175,"end":40235},{"type":"TextQuoteSelector","exact":"negative  MRD  test  result  may  not  indicate  complete  disease  eradication,  but  refers  to disease below the MRD test threshold in the tested sample. Conversely, not all patients who are  MRD-positive  will  relapse.  Of  note,  Mol-MRD  may  remain  detectable  at  low  levels (CRMRD-LL) without prognostic significance, and therefore, are called negative operationally if the MRD values are below the threshold linked to prognosis.67 For instance, in CBF-AML and NPM1-mutant AML, the transcripts may show persistent low-level expression after treatment, but this is not prognostic of relapse.68,70,94-96 The presence of detectable MRD pre-transplant is an independent unfavorable predictor of post-transplant outcome.97-100 However, there is currently no evidence showing benefit of additional courses of intensive chemotherapy prior to transplant in CR1 patients who are MRD-positive. If fit enough, such patients should be considered candidates for a myeloablative conditioning (MAC) regimen or an early taper of post-transplant immunosuppression.9","prefix":" MRD-negative patients. Thus, a ","suffix":"8 Definitions  of  MRD  response"}]}]}
>```
>%%
>*%%PREFIX%%MRD-negative patients. Thus, a%%HIGHLIGHT%% ==negative  MRD  test  result  may  not  indicate  complete  disease  eradication,  but  refers  to disease below the MRD test threshold in the tested sample. Conversely, not all patients who are  MRD-positive  will  relapse.  Of  note,  Mol-MRD  may  remain  detectable  at  low  levels (CRMRD-LL) without prognostic significance, and therefore, are called negative operationally if the MRD values are below the threshold linked to prognosis.67 For instance, in CBF-AML and NPM1-mutant AML, the transcripts may show persistent low-level expression after treatment, but this is not prognostic of relapse.68,70,94-96 The presence of detectable MRD pre-transplant is an independent unfavorable predictor of post-transplant outcome.97-100 However, there is currently no evidence showing benefit of additional courses of intensive chemotherapy prior to transplant in CR1 patients who are MRD-positive. If fit enough, such patients should be considered candidates for a myeloablative conditioning (MAC) regimen or an early taper of post-transplant immunosuppression.9== %%POSTFIX%%8 Definitions  of  MRD  response*
>%%LINK%%[[#^lxhz8enzre|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^lxhz8enzre


>%%
>```annotation-json
>{"created":"2022-08-29T08:08:28.641Z","text":"further investigate","updated":"2022-08-29T08:08:28.641Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":40640,"end":40716},{"type":"TextQuoteSelector","exact":" CR, CRi, partial remission (PR), and morphologic leukemia-free state (MLFS)","prefix":"sponse criteria The criteria for","suffix":" have not changed.  CR with part"}]}]}
>```
>%%
>*%%PREFIX%%sponse criteria The criteria for%%HIGHLIGHT%% ==CR, CRi, partial remission (PR), and morphologic leukemia-free state (MLFS)== %%POSTFIX%%have not changed.  CR with part*
>%%LINK%%[[#^of6amvmo7r|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^of6amvmo7r


>%%
>```annotation-json
>{"created":"2022-08-29T08:14:24.275Z","updated":"2022-08-29T08:14:24.275Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":40830,"end":40988},{"type":"TextQuoteSelector","exact":"  morphologic  bone  marrow  blast  clearance  and  partial  recovery  of  both  neutrophils (≥0.5x109/L  [500/μL])  and  platelets  (≥50x109/L  [50,000/μL]) ","prefix":"een introduced for patients with","suffix":" since  those  represent  clinic"}]}]}
>```
>%%
>*%%PREFIX%%een introduced for patients with%%HIGHLIGHT%% ==morphologic  bone  marrow  blast  clearance  and  partial  recovery  of  both  neutrophils (≥0.5x109/L  [500/μL])  and  platelets  (≥50x109/L  [50,000/μL])== %%POSTFIX%%since  those  represent  clinic*
>%%LINK%%[[#^2m452f9c4px|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2m452f9c4px


>%%
>```annotation-json
>{"created":"2022-08-29T08:16:33.235Z","updated":"2022-08-29T08:16:33.235Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":41530,"end":41668},{"type":"TextQuoteSelector","exact":" The  current  response  criteria  expand  MRD  classification  to include patients achieving CRh or CRi without MRD (CRhMRD- or CRiMRD-).","prefix":"ognosis  of  patients  in  CR.1 ","suffix":"  Time window for response asses"}]}]}
>```
>%%
>*%%PREFIX%%ognosis  of  patients  in  CR.1%%HIGHLIGHT%% ==The  current  response  criteria  expand  MRD  classification  to include patients achieving CRh or CRi without MRD (CRhMRD- or CRiMRD-).== %%POSTFIX%%Time window for response asses*
>%%LINK%%[[#^1g258lfibug|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1g258lfibug


>%%
>```annotation-json
>{"created":"2022-08-29T08:19:11.180Z","updated":"2022-08-29T08:19:11.180Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":42358,"end":42492},{"type":"TextQuoteSelector","exact":" Patients evaluable for response but not meeting the criteria for CR, CRh, CRi, MLFS or PR will be categorized as having ‘no response’","prefix":"ponse designation.  No response.","suffix":".   Non-evaluable for response. "}]}]}
>```
>%%
>*%%PREFIX%%ponse designation.  No response.%%HIGHLIGHT%% ==Patients evaluable for response but not meeting the criteria for CR, CRh, CRi, MLFS or PR will be categorized as having ‘no response’== %%POSTFIX%%.   Non-evaluable for response.*
>%%LINK%%[[#^kjgjlichmd|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kjgjlichmd


>%%
>```annotation-json
>{"created":"2022-08-29T08:19:56.312Z","updated":"2022-08-29T08:19:56.312Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":43167,"end":43390},{"type":"TextQuoteSelector","exact":"Relapsed  disease is defined as ≥5% leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (PB) in at least 2 PB samples at least one week apart, or development of new extramedullary disease","prefix":"or response.  Treatment failure ","suffix":".  Refractory disease. If a spec"}]}]}
>```
>%%
>*%%PREFIX%%or response.  Treatment failure%%HIGHLIGHT%% ==Relapsed  disease is defined as ≥5% leukemic blasts in the bone marrow, reappearance of leukemic blasts in peripheral blood (PB) in at least 2 PB samples at least one week apart, or development of new extramedullary disease== %%POSTFIX%%.  Refractory disease. If a spec*
>%%LINK%%[[#^0pqfjeyliw8j|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0pqfjeyliw8j


>%%
>```annotation-json
>{"created":"2022-08-29T08:21:10.066Z","updated":"2022-08-29T08:21:10.066Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":43486,"end":43649},{"type":"TextQuoteSelector","exact":"failure to achieve response after 2 cycles of  intensive  chemotherapy  or  a  pre-determined landmark,  eg,  180  days  after  commencing  less-intensive  therapy","prefix":"eved by a defined landmark (ie, ","suffix":"),  the  patient  will  be desig"}]}]}
>```
>%%
>*%%PREFIX%%eved by a defined landmark (ie,%%HIGHLIGHT%% ==failure to achieve response after 2 cycles of  intensive  chemotherapy  or  a  pre-determined landmark,  eg,  180  days  after  commencing  less-intensive  therapy== %%POSTFIX%%),  the  patient  will  be desig*
>%%LINK%%[[#^6z31qx48sjs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6z31qx48sjs


>%%
>```annotation-json
>{"created":"2022-08-29T08:26:16.635Z","updated":"2022-08-29T08:26:16.635Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":45173,"end":45340},{"type":"TextQuoteSelector","exact":"For drugs that add myelosuppression (eg, venetoclax, CPX-351, gemtuzumab ozogomycin), the sole use of a strict CR in the definition of EFS is increasingly challenged. ","prefix":" lack of multivariate analyses. ","suffix":"We recommend broadening the defi"}]}]}
>```
>%%
>*%%PREFIX%%lack of multivariate analyses.%%HIGHLIGHT%% ==For drugs that add myelosuppression (eg, venetoclax, CPX-351, gemtuzumab ozogomycin), the sole use of a strict CR in the definition of EFS is increasingly challenged.== %%POSTFIX%%We recommend broadening the defi*
>%%LINK%%[[#^evt6hd8ro9l|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^evt6hd8ro9l


>%%
>```annotation-json
>{"created":"2022-08-29T08:41:33.213Z","updated":"2022-08-29T08:41:33.213Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":45843,"end":46167},{"type":"TextQuoteSelector","exact":"Patients  who  die  before  reaching  the  response  landmark  and  prior to/without  response  assessments  are  considered  treatment  failures  and  should  have  the event recorded at day 1 of registration/ randomization. Patients alive but non-evaluable for response are censored at day 1 of registration/ randomization","prefix":"gnment in randomized  trials).  ","suffix":". To enable consistency in trial"}]}]}
>```
>%%
>*%%PREFIX%%gnment in randomized  trials).%%HIGHLIGHT%% ==Patients  who  die  before  reaching  the  response  landmark  and  prior to/without  response  assessments  are  considered  treatment  failures  and  should  have  the event recorded at day 1 of registration/ randomization. Patients alive but non-evaluable for response are censored at day 1 of registration/ randomization== %%POSTFIX%%. To enable consistency in trial*
>%%LINK%%[[#^ufcief8miid|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ufcief8miid


>%%
>```annotation-json
>{"created":"2022-08-29T08:42:27.587Z","text":"further investigate","updated":"2022-08-29T08:42:27.587Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":46514,"end":46762},{"type":"TextQuoteSelector","exact":"The  incorporation  of  MRD  outcomes  as  a  measure  of  treatment  failure  necessitates  the inclusion of new terms incorporating molecular MRD relapse into time to event definitions for EFSMRD, RFSMRD and cumulative incidence of relapse (CIRMR","prefix":"cing less-intensive approaches. ","suffix":"D) (Table 9). For each study, cl"}]}]}
>```
>%%
>*%%PREFIX%%cing less-intensive approaches.%%HIGHLIGHT%% ==The  incorporation  of  MRD  outcomes  as  a  measure  of  treatment  failure  necessitates  the inclusion of new terms incorporating molecular MRD relapse into time to event definitions for EFSMRD, RFSMRD and cumulative incidence of relapse (CIRMR== %%POSTFIX%%D) (Table 9). For each study, cl*
>%%LINK%%[[#^ybu8uth9f|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^ybu8uth9f


>%%
>```annotation-json
>{"created":"2022-08-29T08:43:20.451Z","updated":"2022-08-29T08:43:20.451Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":47460,"end":47606},{"type":"TextQuoteSelector","exact":"A  short  delay  in  starting  treatment  to stabilize patients and identify the best treatment option is recommended to optimize clinical outcome","prefix":"tionable  targets  (Table  4).  ","suffix":".102 If hyperleukocytosis is pre"}]}]}
>```
>%%
>*%%PREFIX%%tionable  targets  (Table  4).%%HIGHLIGHT%% ==A  short  delay  in  starting  treatment  to stabilize patients and identify the best treatment option is recommended to optimize clinical outcome== %%POSTFIX%%.102 If hyperleukocytosis is pre*
>%%LINK%%[[#^d894xbrss8q|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^d894xbrss8q


>%%
>```annotation-json
>{"created":"2022-08-29T08:43:50.016Z","updated":"2022-08-29T08:43:50.016Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":47609,"end":48047},{"type":"TextQuoteSelector","exact":"2 If hyperleukocytosis is present, immediate cytoreduction is advised (see section on Management of Special Situations). If a patient cannot tolerate an active intensive or non-intensive treatment option, the purpose of therapy is to optimize quality of life and decrease the incidence of cytopenia-related complications with transfusion and other supportive care measures and early involvement of palliative care services as appropriate.","prefix":" to optimize clinical outcome.10","suffix":" The survival of patients with A"}]}]}
>```
>%%
>*%%PREFIX%%to optimize clinical outcome.10%%HIGHLIGHT%% ==2 If hyperleukocytosis is present, immediate cytoreduction is advised (see section on Management of Special Situations). If a patient cannot tolerate an active intensive or non-intensive treatment option, the purpose of therapy is to optimize quality of life and decrease the incidence of cytopenia-related complications with transfusion and other supportive care measures and early involvement of palliative care services as appropriate.== %%POSTFIX%%The survival of patients with A*
>%%LINK%%[[#^6rhv8uo3vhb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6rhv8uo3vhb


>%%
>```annotation-json
>{"created":"2022-08-29T08:44:10.473Z","updated":"2022-08-29T08:44:10.473Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":48048,"end":48217},{"type":"TextQuoteSelector","exact":"The survival of patients with AML that are related to previous therapy overall remains poor which is mainly due to the high frequency of adverse (cyto)genetic features,1","prefix":"e care services as appropriate. ","suffix":"03,104 but also to the sequelae "}]}]}
>```
>%%
>*%%PREFIX%%e care services as appropriate.%%HIGHLIGHT%% ==The survival of patients with AML that are related to previous therapy overall remains poor which is mainly due to the high frequency of adverse (cyto)genetic features,1== %%POSTFIX%%03,104 but also to the sequelae*
>%%LINK%%[[#^bzd7dy2pmf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^bzd7dy2pmf


>%%
>```annotation-json
>{"created":"2022-08-29T08:45:26.029Z","text":"further investigate","updated":"2022-08-29T08:45:26.029Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":48661,"end":48979},{"type":"TextQuoteSelector","exact":"Anthracyclines and cytarabine remain the backbone of intensive chemotherapy. Alternative options  are  FLAG-IDA  and  mitoxantrone-based  cytarabine  regimens  (Table  10).  It  has become  standard  to  incorporate  the  kinase  inhibitor  midostaurin  into  first-line  therapy  for patients  with  FLT3-mutant  AML.","prefix":"nsive therapy Induction therapy ","suffix":"  Midostaurin  improved  4-year "}]}]}
>```
>%%
>*%%PREFIX%%nsive therapy Induction therapy%%HIGHLIGHT%% ==Anthracyclines and cytarabine remain the backbone of intensive chemotherapy. Alternative options  are  FLAG-IDA  and  mitoxantrone-based  cytarabine  regimens  (Table  10).  It  has become  standard  to  incorporate  the  kinase  inhibitor  midostaurin  into  first-line  therapy  for patients  with  FLT3-mutant  AML.== %%POSTFIX%%Midostaurin  improved  4-year*
>%%LINK%%[[#^2ddsal5lqy4|show annotation]]
>%%COMMENT%%
>further investigate
>%%TAGS%%
>
^2ddsal5lqy4


>%%
>```annotation-json
>{"created":"2022-08-29T08:46:28.854Z","updated":"2022-08-29T08:46:28.854Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":50536,"end":50663},{"type":"TextQuoteSelector","exact":"Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 IgG4 antibody chemically linked to a calicheamicin-based cytotoxic warhead.","prefix":" placebo arms, respectively.111 ","suffix":" Following a history of initial "}]}]}
>```
>%%
>*%%PREFIX%%placebo arms, respectively.111%%HIGHLIGHT%% ==Gemtuzumab-ozogamicin (GO) is a humanized anti-CD33 IgG4 antibody chemically linked to a calicheamicin-based cytotoxic warhead.== %%POSTFIX%%Following a history of initial*
>%%LINK%%[[#^swscxb4ltok|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^swscxb4ltok


>%%
>```annotation-json
>{"created":"2022-08-29T08:51:50.740Z","updated":"2022-08-29T08:51:50.740Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":51760,"end":51876},{"type":"TextQuoteSelector","exact":"CPX-351 is a dual-drug liposomal formulation that encapsulates cytarabine/daunorubicin in a 5:1  fixed  molar  ratio","prefix":"lso  be efficacious.114,116,117 ","suffix":".118  In  an  open  label  phase"}]}]}
>```
>%%
>*%%PREFIX%%lso  be efficacious.114,116,117%%HIGHLIGHT%% ==CPX-351 is a dual-drug liposomal formulation that encapsulates cytarabine/daunorubicin in a 5:1  fixed  molar  ratio== %%POSTFIX%%.118  In  an  open  label  phase*
>%%LINK%%[[#^p6looxpnck|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^p6looxpnck


>%%
>```annotation-json
>{"created":"2022-08-29T08:52:18.577Z","updated":"2022-08-29T08:52:18.577Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":52769,"end":52899},{"type":"TextQuoteSelector","exact":"After attainment of CR (or CRh/CRi), patients are consolidated ideally with  regimens that include intermediate-dose cytarabine.12","prefix":"ior MPN.  Consolidation therapy ","suffix":"1 Consecutive administration on "}]}]}
>```
>%%
>*%%PREFIX%%ior MPN.  Consolidation therapy%%HIGHLIGHT%% ==After attainment of CR (or CRh/CRi), patients are consolidated ideally with  regimens that include intermediate-dose cytarabine.12== %%POSTFIX%%1 Consecutive administration on*
>%%LINK%%[[#^pchv6hfh6o9|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^pchv6hfh6o9


>%%
>```annotation-json
>{"created":"2022-08-29T08:53:07.559Z","updated":"2022-08-29T08:53:07.559Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":53431,"end":53731},{"type":"TextQuoteSelector","exact":" assessment of MRD in CR (or CRh/CRi) is recommended for patients with non-adverse risk in first remission to inform consolidation treatment choice. For  patients  with  an  estimated  relapse  risk  exceeding  35%-40%,  consolidation  with allogeneic HCT remains the preferred post-remission option.","prefix":"dition to baseline risk factors,","suffix":"127 These include patients with "}]}]}
>```
>%%
>*%%PREFIX%%dition to baseline risk factors,%%HIGHLIGHT%% ==assessment of MRD in CR (or CRh/CRi) is recommended for patients with non-adverse risk in first remission to inform consolidation treatment choice. For  patients  with  an  estimated  relapse  risk  exceeding  35%-40%,  consolidation  with allogeneic HCT remains the preferred post-remission option.== %%POSTFIX%%127 These include patients with*
>%%LINK%%[[#^cgw5mufxtde|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^cgw5mufxtde


>%%
>```annotation-json
>{"created":"2022-08-29T08:53:16.877Z","updated":"2022-08-29T08:53:16.877Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":54084,"end":54220},{"type":"TextQuoteSelector","exact":" In the subset of patients receiving induction with a FLT3 inhibitor, GO or CPX-351, these agents may be incorporated into consolidation","prefix":"ogeneic HCT is not available.128","suffix":" (Table 10). Maintenance therapy"}]}]}
>```
>%%
>*%%PREFIX%%ogeneic HCT is not available.128%%HIGHLIGHT%% ==In the subset of patients receiving induction with a FLT3 inhibitor, GO or CPX-351, these agents may be incorporated into consolidation== %%POSTFIX%%(Table 10). Maintenance therapy*
>%%LINK%%[[#^6a30f8bo89d|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6a30f8bo89d


>%%
>```annotation-json
>{"created":"2022-08-29T08:57:29.574Z","updated":"2022-08-29T08:57:29.574Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":54319,"end":54712},{"type":"TextQuoteSelector","exact":". In most previous trials, maintenance  therapy  has  been  administered  for  a  defined  period  of  time  in  patients  who achieved remission after intensive chemotherapy. The FDA defines maintenance therapy for AML as an extended but time-limited course of treatment, that is usually less toxic, given after  achievement  of  CR  with  the  objective  of  reducing  the  risk  of  relapse","prefix":"inition of “maintenance therapy”","suffix":".  Thus,  a  trial designed  to "}]}]}
>```
>%%
>*%%PREFIX%%inition of “maintenance therapy”%%HIGHLIGHT%% ==. In most previous trials, maintenance  therapy  has  been  administered  for  a  defined  period  of  time  in  patients  who achieved remission after intensive chemotherapy. The FDA defines maintenance therapy for AML as an extended but time-limited course of treatment, that is usually less toxic, given after  achievement  of  CR  with  the  objective  of  reducing  the  risk  of  relapse== %%POSTFIX%%.  Thus,  a  trial designed  to*
>%%LINK%%[[#^786zzm8cns|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^786zzm8cns


>%%
>```annotation-json
>{"created":"2022-08-29T08:58:42.890Z","updated":"2022-08-29T08:58:42.890Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":55213,"end":55365},{"type":"TextQuoteSelector","exact":" azacitidine  maintenance therapy,  administered  subcutaneously  for  up  to  12  cycles,  improved  disease-free  survival compared to no maintenance.","prefix":"cles  of  intensive  induction, ","suffix":"130 An orally administered versi"}]}]}
>```
>%%
>*%%PREFIX%%cles  of  intensive  induction,%%HIGHLIGHT%% ==azacitidine  maintenance therapy,  administered  subcutaneously  for  up  to  12  cycles,  improved  disease-free  survival compared to no maintenance.== %%POSTFIX%%130 An orally administered versi*
>%%LINK%%[[#^kb3ndthxhue|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kb3ndthxhue


>%%
>```annotation-json
>{"created":"2022-08-29T09:07:03.754Z","updated":"2022-08-29T09:07:03.754Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":56710,"end":56866},{"type":"TextQuoteSelector","exact":"Patients who received  midostaurin during induction and consolidation may continue these agents in maintenance in line with the reported phase 3 experience.","prefix":"and 20% not any consolidation.  ","suffix":"106  Patients not considered can"}]}]}
>```
>%%
>*%%PREFIX%%and 20% not any consolidation.%%HIGHLIGHT%% ==Patients who received  midostaurin during induction and consolidation may continue these agents in maintenance in line with the reported phase 3 experience.== %%POSTFIX%%106  Patients not considered can*
>%%LINK%%[[#^xidmuwj3uzj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xidmuwj3uzj


>%%
>```annotation-json
>{"created":"2022-08-29T09:07:53.054Z","updated":"2022-08-29T09:07:53.054Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":57596,"end":57765},{"type":"TextQuoteSelector","exact":"Compared  to  azacitidine  alone,  addition  of  the  BCL2 inhibitor venetoclax improved clinical response (CR/CRi 66.4% vs 28.3%) and median OS (14.7  vs  9.6  months),","prefix":"ve  chemotherapy  (Table  11).  ","suffix":"  establishing  a  new  standard"}]}]}
>```
>%%
>*%%PREFIX%%ve  chemotherapy  (Table  11).%%HIGHLIGHT%% ==Compared  to  azacitidine  alone,  addition  of  the  BCL2 inhibitor venetoclax improved clinical response (CR/CRi 66.4% vs 28.3%) and median OS (14.7  vs  9.6  months),== %%POSTFIX%%establishing  a  new  standard*
>%%LINK%%[[#^inwlqm8o15j|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^inwlqm8o15j


>%%
>```annotation-json
>{"created":"2022-08-29T09:09:04.973Z","updated":"2022-08-29T09:09:04.973Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":58087,"end":58527},{"type":"TextQuoteSelector","exact":", phase 1b/2 studies suggest that clinical outcomes  with  decitabine  plus  venetoclax  are  similar  to  the  azacitidine  plus  venetoclax combination.136  For  patients  failing  frontline  venetoclax-based  therapy,  prognosis  appears very  poor.137  For  patients  unable  to  receive  a  hypomethylating  agent  (HMA),  low-dose cytarabine  (LDC)  in  combination  with  venetoclax  represents  an  alternative  treatment option.138","prefix":"ed in randomized clinical trials","suffix":"    Although  an  open-label  ra"}]}]}
>```
>%%
>*%%PREFIX%%ed in randomized clinical trials%%HIGHLIGHT%% ==, phase 1b/2 studies suggest that clinical outcomes  with  decitabine  plus  venetoclax  are  similar  to  the  azacitidine  plus  venetoclax combination.136  For  patients  failing  frontline  venetoclax-based  therapy,  prognosis  appears very  poor.137  For  patients  unable  to  receive  a  hypomethylating  agent  (HMA),  low-dose cytarabine  (LDC)  in  combination  with  venetoclax  represents  an  alternative  treatment option.138== %%POSTFIX%%Although  an  open-label  ra*
>%%LINK%%[[#^o3g9xi66j8r|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^o3g9xi66j8r


>%%
>```annotation-json
>{"created":"2022-08-29T09:09:31.218Z","updated":"2022-08-29T09:09:31.218Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":58820,"end":59147},{"type":"TextQuoteSelector","exact":"For newly diagnosed patients with IDH1 mutation, results from a randomized study indicate that  the  IDH1  inhibitor  ivosidenib  plus  azacitidine  improves  EFS  (HR  0.33  [95%  CI  0.16-0.69]),  clinical  response  (CR/CRh  52.8  vs  17.6%),  and  median  OS  (24.0 vs 7.9  months), compared to azacitidine plus placebo.140","prefix":"native non-intensive option.139 ","suffix":" To identify patients suitable f"}]}]}
>```
>%%
>*%%PREFIX%%native non-intensive option.139%%HIGHLIGHT%% ==For newly diagnosed patients with IDH1 mutation, results from a randomized study indicate that  the  IDH1  inhibitor  ivosidenib  plus  azacitidine  improves  EFS  (HR  0.33  [95%  CI  0.16-0.69]),  clinical  response  (CR/CRh  52.8  vs  17.6%),  and  median  OS  (24.0 vs 7.9  months), compared to azacitidine plus placebo.140== %%POSTFIX%%To identify patients suitable f*
>%%LINK%%[[#^qx433ddp3we|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qx433ddp3we


>%%
>```annotation-json
>{"created":"2022-08-29T09:09:48.097Z","updated":"2022-08-29T09:09:48.097Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":59299,"end":59504},{"type":"TextQuoteSelector","exact":"Patients  with  IDH1/2-mutated  AML  who  are  considered  too  frail  to  tolerate  HMA-based treatment  may  be  offered  best  supportive  care  or  monotherapy  with  targeted  IDH1/IDH2 inhibitors.141","prefix":"ts  with  AML  is  recommended. ","suffix":" In  patients  receiving  HMA-ba"}]}]}
>```
>%%
>*%%PREFIX%%ts  with  AML  is  recommended.%%HIGHLIGHT%% ==Patients  with  IDH1/2-mutated  AML  who  are  considered  too  frail  to  tolerate  HMA-based treatment  may  be  offered  best  supportive  care  or  monotherapy  with  targeted  IDH1/IDH2 inhibitors.141== %%POSTFIX%%In  patients  receiving  HMA-ba*
>%%LINK%%[[#^k9odhqsf38s|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^k9odhqsf38s


>%%
>```annotation-json
>{"created":"2022-08-29T09:15:45.561Z","updated":"2022-08-29T09:15:45.561Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":61835,"end":62278},{"type":"TextQuoteSelector","exact":"9  In  general,  after  cytoreduction  has  been  achieved,  allogeneic  HCT  is recommended. If HCT is not a realistic option (eg, in the older patient), disease control using a  non-intensive  option,  such  as  HMA  with  or  without  venetoclax may  be  appropriate.  For patients with relapsed/refractory FLT3-mutated disease, the kinase inhibitor gilteritinib has been approved based on a randomized trial showing improved response rates","prefix":" or prior history of  HCT.148,14","suffix":" (CR 21.1% vs 10.5%) and median "}]}]}
>```
>%%
>*%%PREFIX%%or prior history of  HCT.148,14%%HIGHLIGHT%% ==9  In  general,  after  cytoreduction  has  been  achieved,  allogeneic  HCT  is recommended. If HCT is not a realistic option (eg, in the older patient), disease control using a  non-intensive  option,  such  as  HMA  with  or  without  venetoclax may  be  appropriate.  For patients with relapsed/refractory FLT3-mutated disease, the kinase inhibitor gilteritinib has been approved based on a randomized trial showing improved response rates== %%POSTFIX%%(CR 21.1% vs 10.5%) and median*
>%%LINK%%[[#^rwo1xmq4dc|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^rwo1xmq4dc


>%%
>```annotation-json
>{"created":"2022-08-29T09:16:06.765Z","updated":"2022-08-29T09:16:06.765Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":62579,"end":62649},{"type":"TextQuoteSelector","exact":"the  clinical  benefit  of  post-HCT  gilteritinib  remains  uncertain","prefix":"teritinib 30-90 days post-HCT,  ","suffix":".  In  addition,  only 5.7%  of "}]}]}
>```
>%%
>*%%PREFIX%%teritinib 30-90 days post-HCT,%%HIGHLIGHT%% ==the  clinical  benefit  of  post-HCT  gilteritinib  remains  uncertain== %%POSTFIX%%.  In  addition,  only 5.7%  of*
>%%LINK%%[[#^hr5ew8njnji|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^hr5ew8njnji


>%%
>```annotation-json
>{"created":"2022-08-29T09:16:52.329Z","updated":"2022-08-29T09:16:52.329Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":63205,"end":63484},{"type":"TextQuoteSelector","exact":"For  patients  with  relapsed/refractory  IDH1/IDH2-mutant  AML,  salvage  with  ivosidenib  or enasidenib is a possibility since these IDH inhibitors induce CR rates in the range of 20% and  overall  response,  including  hematologic  improvement  in  approximately  40%.151-153","prefix":" Agency (EMA) granted approval. ","suffix":" Median  time  required  to  att"}]}]}
>```
>%%
>*%%PREFIX%%Agency (EMA) granted approval.%%HIGHLIGHT%% ==For  patients  with  relapsed/refractory  IDH1/IDH2-mutant  AML,  salvage  with  ivosidenib  or enasidenib is a possibility since these IDH inhibitors induce CR rates in the range of 20% and  overall  response,  including  hematologic  improvement  in  approximately  40%.151-153== %%POSTFIX%%Median  time  required  to  att*
>%%LINK%%[[#^xllysf2etp8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xllysf2etp8


>%%
>```annotation-json
>{"created":"2022-08-29T09:22:00.654Z","updated":"2022-08-29T09:22:00.654Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":64304,"end":64654},{"type":"TextQuoteSelector","exact":" Advances allowing for the use of partially matched unrelated donors, cord blood, and haplo-identical family members mean that an allogeneic donor can be found for the majority of patients in need. Non-myeloablative (NMA) and reduced intensity conditioning (RIC) regimens make allogeneic HCT possible in patients up to age 80 at experienced centers.1","prefix":"ation for allogeneic HCT.155,156","suffix":"57,158 With newly approved metho"}]}]}
>```
>%%
>*%%PREFIX%%ation for allogeneic HCT.155,156%%HIGHLIGHT%% ==Advances allowing for the use of partially matched unrelated donors, cord blood, and haplo-identical family members mean that an allogeneic donor can be found for the majority of patients in need. Non-myeloablative (NMA) and reduced intensity conditioning (RIC) regimens make allogeneic HCT possible in patients up to age 80 at experienced centers.1== %%POSTFIX%%57,158 With newly approved metho*
>%%LINK%%[[#^mfp18r3pxo|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mfp18r3pxo


>%%
>```annotation-json
>{"created":"2022-08-29T09:22:41.912Z","updated":"2022-08-29T09:22:41.912Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":65375,"end":65667},{"type":"TextQuoteSelector","exact":"The decision to perform allogeneic HCT during first remission depends on the risk-benefit ratio  (ie,  non-relapse  mortality  [NRM]  and  disability/reduction  in  relapse  risk)  based  on cytogenetic and molecular genetic features of disease at presentation and response to initial therapy","prefix":" Indications for allogeneic HCT ","suffix":",  as  well  as  patient,  donor"}]}]}
>```
>%%
>*%%PREFIX%%Indications for allogeneic HCT%%HIGHLIGHT%% ==The decision to perform allogeneic HCT during first remission depends on the risk-benefit ratio  (ie,  non-relapse  mortality  [NRM]  and  disability/reduction  in  relapse  risk)  based  on cytogenetic and molecular genetic features of disease at presentation and response to initial therapy== %%POSTFIX%%,  as  well  as  patient,  donor*
>%%LINK%%[[#^2ee15j9bsm2|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2ee15j9bsm2


>%%
>```annotation-json
>{"created":"2022-08-29T09:24:36.161Z","updated":"2022-08-29T09:24:36.161Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":65850,"end":66285},{"type":"TextQuoteSelector","exact":"For  patients  with  favorable-risk  disease,  allogeneic  HCT  in  CR1  is  generally  not recommended  except  for  those  with  inadequate  clearance  of  MRD.69,161-163  In  contrast, allogeneic HCT is recommended for patients with adverse-risk AML and for the majority of those with intermediate-risk disease, although quite a few centers rely on the presence of MRD to guide their decision based on the predicted risk of relapse.","prefix":" is predicted to be >35-40%.127 ","suffix":" For patients age 60 or more,  m"}]}]}
>```
>%%
>*%%PREFIX%%is predicted to be >35-40%.127%%HIGHLIGHT%% ==For  patients  with  favorable-risk  disease,  allogeneic  HCT  in  CR1  is  generally  not recommended  except  for  those  with  inadequate  clearance  of  MRD.69,161-163  In  contrast, allogeneic HCT is recommended for patients with adverse-risk AML and for the majority of those with intermediate-risk disease, although quite a few centers rely on the presence of MRD to guide their decision based on the predicted risk of relapse.== %%POSTFIX%%For patients age 60 or more,  m*
>%%LINK%%[[#^cs3yis9b3ci|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^cs3yis9b3ci


>%%
>```annotation-json
>{"created":"2022-08-29T09:26:00.923Z","updated":"2022-08-29T09:26:00.923Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":67546,"end":67734},{"type":"TextQuoteSelector","exact":" The  modified  European  Society  of Blood and Marrow Transplantation (EBMT) risk score combines both patient and disease risk factors thus predicting OS rather than NRM or relapse risk.1","prefix":" of  patient  comorbidities.170 ","suffix":"71 Preparative regimen intensity"}]}]}
>```
>%%
>*%%PREFIX%%of  patient  comorbidities.170%%HIGHLIGHT%% ==The  modified  European  Society  of Blood and Marrow Transplantation (EBMT) risk score combines both patient and disease risk factors thus predicting OS rather than NRM or relapse risk.1== %%POSTFIX%%71 Preparative regimen intensity*
>%%LINK%%[[#^68wofnqvrsx|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^68wofnqvrsx


>%%
>```annotation-json
>{"created":"2022-08-29T09:27:34.398Z","updated":"2022-08-29T09:27:34.398Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":69167,"end":69555},{"type":"TextQuoteSelector","exact":" post-transplant cyclophosphamide GVHD prophylaxis is tolerable and results in encouraging outcomes using mismatched unrelated and haplo-identical donors substantially widens the donor pool.176-179 The use of single or double cord blood units with a high  nucleated  cell  dose  also  results  in  excellent  outcomes,  particularly  in  patients  with evidence  of  pre-transplant  MRD.1","prefix":"r. The recent demonstration that","suffix":"79,180  Current  data  support  "}]}]}
>```
>%%
>*%%PREFIX%%r. The recent demonstration that%%HIGHLIGHT%% ==post-transplant cyclophosphamide GVHD prophylaxis is tolerable and results in encouraging outcomes using mismatched unrelated and haplo-identical donors substantially widens the donor pool.176-179 The use of single or double cord blood units with a high  nucleated  cell  dose  also  results  in  excellent  outcomes,  particularly  in  patients  with evidence  of  pre-transplant  MRD.1== %%POSTFIX%%79,180  Current  data  support*
>%%LINK%%[[#^xtc1in5cnwf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xtc1in5cnwf


>%%
>```annotation-json
>{"created":"2022-08-29T09:28:20.381Z","updated":"2022-08-29T09:28:20.381Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":70630,"end":71194},{"type":"TextQuoteSelector","exact":" In  patients  allografted  for FLT3-mutated  AML,  randomized  studies  show  that  maintenance  with  the  FLT3  inhibitor sorafenib, although sometimes challenging to deliver, reduces the risk of relapse, suggesting that the use of a FLT3 inhibitor is a reasonable option.182,183 A randomized trial examining the benefit of post-transplant maintenance with the second generation FLT3 inhibitor gilteritinib in this  patient  population  is  in  progress.  There  is  less  evidence  supporting  the  use  of  other agents as post-transplant maintenance in AML. ","prefix":"  prevent  disease  recurrence. ","suffix":"A randomized study of maintenanc"}]}]}
>```
>%%
>*%%PREFIX%%prevent  disease  recurrence.%%HIGHLIGHT%% ==In  patients  allografted  for FLT3-mutated  AML,  randomized  studies  show  that  maintenance  with  the  FLT3  inhibitor sorafenib, although sometimes challenging to deliver, reduces the risk of relapse, suggesting that the use of a FLT3 inhibitor is a reasonable option.182,183 A randomized trial examining the benefit of post-transplant maintenance with the second generation FLT3 inhibitor gilteritinib in this  patient  population  is  in  progress.  There  is  less  evidence  supporting  the  use  of  other agents as post-transplant maintenance in AML.== %%POSTFIX%%A randomized study of maintenanc*
>%%LINK%%[[#^6p6rjhzgtg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6p6rjhzgtg


>%%
>```annotation-json
>{"created":"2022-08-29T09:30:06.839Z","updated":"2022-08-29T09:30:06.839Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":77969,"end":79062},{"type":"TextQuoteSelector","exact":" Drug development strategies have focused until now primarily on single-agent dose finding studies in the relapsed setting, which have led to successful approvals of targeted therapies, such as FLT3, IDH1, and IDH2 inhibitors, and  is  the  pattern  for  the  current  evaluation  of  menin  inhibitors  for  patients  with  KMT2A-rearrangements or NPM1 mutations.109,151,152,191 Other  agents  (ie,  epigenetically  targeted  therapies)  and  immunotherapy  approaches including bi-specific T-cell engaging antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T cells or NK cells are likely to be most effective in the setting of MRD, in frontline, or early salvage combination approaches.190,192,193 Although of limited single agent activity, the CD47 inhibitor magrolimab has demonstrated preliminary activity in combination with azacitidine in patients with newly diagnosed MDS and AML, even in the setting of TP53-mutated disease. Trials of various inhibitors of the CD47-SIRP-alpha macrophage checkpoint are currently under various stages of early clinical evaluation.1","prefix":"improve AML patient outcomes.190","suffix":"94 Due to the changing therapeut"}]}]}
>```
>%%
>*%%PREFIX%%improve AML patient outcomes.190%%HIGHLIGHT%% ==Drug development strategies have focused until now primarily on single-agent dose finding studies in the relapsed setting, which have led to successful approvals of targeted therapies, such as FLT3, IDH1, and IDH2 inhibitors, and  is  the  pattern  for  the  current  evaluation  of  menin  inhibitors  for  patients  with  KMT2A-rearrangements or NPM1 mutations.109,151,152,191 Other  agents  (ie,  epigenetically  targeted  therapies)  and  immunotherapy  approaches including bi-specific T-cell engaging antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR) T cells or NK cells are likely to be most effective in the setting of MRD, in frontline, or early salvage combination approaches.190,192,193 Although of limited single agent activity, the CD47 inhibitor magrolimab has demonstrated preliminary activity in combination with azacitidine in patients with newly diagnosed MDS and AML, even in the setting of TP53-mutated disease. Trials of various inhibitors of the CD47-SIRP-alpha macrophage checkpoint are currently under various stages of early clinical evaluation.1== %%POSTFIX%%94 Due to the changing therapeut*
>%%LINK%%[[#^2r98ugki2w3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2r98ugki2w3


>%%
>```annotation-json
>{"created":"2022-08-29T09:30:46.198Z","updated":"2022-08-29T09:30:46.198Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":79295,"end":79554},{"type":"TextQuoteSelector","exact":"The evaluation of so-called “triplet” therapies is now an increasingly common clinical trial design for “chemotherapy-ineligible\" patients, which involves the evaluation of a third agent (either approved or investigational) to the HMA and venetoclax “backbone","prefix":"mbinations is now more complex. ","suffix":"”. New combination trials in int"}]}]}
>```
>%%
>*%%PREFIX%%mbinations is now more complex.%%HIGHLIGHT%% ==The evaluation of so-called “triplet” therapies is now an increasingly common clinical trial design for “chemotherapy-ineligible" patients, which involves the evaluation of a third agent (either approved or investigational) to the HMA and venetoclax “backbone== %%POSTFIX%%”. New combination trials in int*
>%%LINK%%[[#^iihwsdal1a8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^iihwsdal1a8


>%%
>```annotation-json
>{"created":"2022-08-29T09:32:01.377Z","updated":"2022-08-29T09:32:01.377Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":80634,"end":81049},{"type":"TextQuoteSelector","exact":"A white blood cell count (WBC) >100 x 109/L is generally defined as hyperleukocytosis and associated with increased induction mortality mainly due to hemorrhagic events, tumor lysis syndrome, and the risk for clinical leukostasis syndrome.196 Hydroxyurea (up to 50-60 mg/kg per day) is most commonly used to lower the WBC below 25 x 109/L, particularly before the commencement of HMA- or venetoclax-based treatments","prefix":"ommendations  Page 21 of 54   21","suffix":". Clinical leukostasis syndrome "}]}]}
>```
>%%
>*%%PREFIX%%ommendations  Page 21 of 54   21%%HIGHLIGHT%% ==A white blood cell count (WBC) >100 x 109/L is generally defined as hyperleukocytosis and associated with increased induction mortality mainly due to hemorrhagic events, tumor lysis syndrome, and the risk for clinical leukostasis syndrome.196 Hydroxyurea (up to 50-60 mg/kg per day) is most commonly used to lower the WBC below 25 x 109/L, particularly before the commencement of HMA- or venetoclax-based treatments== %%POSTFIX%%. Clinical leukostasis syndrome*
>%%LINK%%[[#^0wfsj81tlggj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^0wfsj81tlggj


>%%
>```annotation-json
>{"created":"2022-08-29T09:32:38.118Z","updated":"2022-08-29T09:32:38.118Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":81654,"end":81838},{"type":"TextQuoteSelector","exact":"Other special situations requiring therapeutic intervention are the presence of disseminated intravascular coagulation (DIC), tumor lysis syndrome (TLS), and differentiation syndrome. ","prefix":" with hyperleukocytosis.199,200 ","suffix":"DIC can be screened for by using"}]}]}
>```
>%%
>*%%PREFIX%%with hyperleukocytosis.199,200%%HIGHLIGHT%% ==Other special situations requiring therapeutic intervention are the presence of disseminated intravascular coagulation (DIC), tumor lysis syndrome (TLS), and differentiation syndrome.== %%POSTFIX%%DIC can be screened for by using*
>%%LINK%%[[#^ocscnntul8p|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ocscnntul8p


>%%
>```annotation-json
>{"created":"2022-08-29T09:33:00.326Z","updated":"2022-08-29T09:33:00.326Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":82033,"end":82402},{"type":"TextQuoteSelector","exact":"1 Special attention to TLS is required in patients with hyperleukocytosis, or with  venetoclax-based  treatments  (Table  12).  Close  monitoring  for  signs  of  differentiation syndrome  such  as  unexplained  fever,  lung  oedema,  weight  gain,  pulmonary  infiltrates, hypoxia and dyspnea is necessary, particularly in patients on treatment with IDH inhibitors.202","prefix":"  initiation  of chemotherapy.20","suffix":"  Supportive care Anti-infectiou"}]}]}
>```
>%%
>*%%PREFIX%%initiation  of chemotherapy.20%%HIGHLIGHT%% ==1 Special attention to TLS is required in patients with hyperleukocytosis, or with  venetoclax-based  treatments  (Table  12).  Close  monitoring  for  signs  of  differentiation syndrome  such  as  unexplained  fever,  lung  oedema,  weight  gain,  pulmonary  infiltrates, hypoxia and dyspnea is necessary, particularly in patients on treatment with IDH inhibitors.202== %%POSTFIX%%Supportive care Anti-infectiou*
>%%LINK%%[[#^xaye03o7pu|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xaye03o7pu


>%%
>```annotation-json
>{"created":"2022-08-29T09:34:02.421Z","updated":"2022-08-29T09:34:02.421Z","document":{"title":"blood.2022016867.pdf","link":[{"href":"urn:x-pdf:78f2cff2ccc1d2e22eaad02d8ce27fdd"},{"href":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf"}],"documentFingerprint":"78f2cff2ccc1d2e22eaad02d8ce27fdd"},"uri":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/blood.2022016867.pdf","selector":[{"type":"TextPositionSelector","start":82642,"end":82894},{"type":"TextQuoteSelector","exact":"recommend antifungal prophylaxis with posaconazole during remission induction therapy,203 whereas  there  is  not  enough  evidence  from  randomized  trials  on  antiviral  prophylaxis  for herpes  simplex  virus  in  patients  with  acute  leukemia,2","prefix":"  There  is  good  evidence  to ","suffix":"04  and  no  evidence  for  a  b"}]}]}
>```
>%%
>*%%PREFIX%%There  is  good  evidence  to%%HIGHLIGHT%% ==recommend antifungal prophylaxis with posaconazole during remission induction therapy,203 whereas  there  is  not  enough  evidence  from  randomized  trials  on  antiviral  prophylaxis  for herpes  simplex  virus  in  patients  with  acute  leukemia,2== %%POSTFIX%%04  and  no  evidence  for  a  b*
>%%LINK%%[[#^js7yu1j3bn7|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^js7yu1j3bn7
